Payload Information

General Information of This Payload

Payload ID	PAY0KPOZO
Name	Genistein
Synonyms	Genistein; 446-72-0; Prunetol; 4',5,7-Trihydroxyisoflavone; Genisterin; Genisteol; Sophoricol; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyisoflavone; Bonistein; Genestein; Differenol A; NPI 031L; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-; C.I. 75610; SIPI 807-1; MFCD00016952; NSC 36586; CCRIS 7675; 4',5, 7-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; NSC36586; EINECS 207-174-9; UNII-DH2M523P0H; NSC-36586; Genistein [USAN]; Lactoferrin-genistein; BRN 0263823; DH2M523P0H; NPI-031L; DTXSID5022308; ISOFLAVONE, 4',5,7-TRIHYDROXY-; CHEBI:28088; HSDB 7475; BIO-300; SIPI-807-1; CHEMBL44; FW-635I-2; Bio 300; PTI G4660 (Genistein); MLS000738127; DTXCID002308; STO514; PTI G4660; PTI-G4660; SIPI-9764-I; PTI-G 4660; 5-18-04-00594 (Beilstein Handbook Reference); TNP00151; Genistein (USAN); GENISTEIN (ENDOCRINE DISRUPTER); GEN; NCGC00015479-09; GENISTEIN (MART.); GENISTEIN [MART.]; G 6649; GENISTEIN (USP-RS); GENISTEIN [USP-RS]; 5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); 690224-00-1; CAS-446-72-0; 4,5,7-Trihydroxyiso-flavone; SR-01000075498; 3kgt; 3kgu; 4′ Genistein, 8; Genistein,(S); Genistein (GEN); IN1327; Genistein (flavonoid); Spectrum_000320; Tocris-1110; 1x7r; 2qa8; Genistein 85% HPLC; GENISTEIN [INN]; SpecPlus_000305; GENISTEIN [MI]; GENISTEIN [HSDB]; GENISTEIN [INCI]; Spectrum2_000638; Spectrum3_000678; Spectrum4_001543; Spectrum5_000106; Lopac-G-6649; ,5,7-Trihydroxyisoflavone; 4',7-Trihydroxyisoflavone; D0L4FS; MolMap_000022; UPCMLD-DP096; G10000; GENISTEIN [WHO-DD]; 4,5,7-Trihydroxyisoflavone; Isoflavone,5,7-trihydroxy-; Lopac0_000520; Oprea1_224620; Oprea1_437815; SCHEMBL19166; BSPBio_002375; KBioGR_002006; KBioGR_002564; KBioSS_000800; KBioSS_002573; NPI031L; SPECTRUM210296; BIDD:ER0113; DivK1c_006401; Genistein, analytical standard; SPBio_000636; 4',5,7-Trihydroxy isoflavone; 4',5,7-trihydroxy-Isoflavone; GTPL2826; MEGxp0_000568; 4,5,7-Trihydroxy Iso-Flavone; UPCMLD-DP096:001; ACon1_001065; BDBM19459; C.I. 75610(ChemID); cid_5280961; KBio1_001345; KBio2_000800; KBio2_002564; KBio2_003368; KBio2_005132; KBio2_005936; KBio2_007700; KBio3_001595; KBio3_003042; CHEBI: 28088; cMAP_000086; Bio1_000445; Bio1_000934; Bio1_001423; HMS2271K09; HMS3261H21; HMS3267K14; HMS3412I13; HMS3428M01; HMS3649B22; HMS3654D17; HMS3676I13; HMS3742I07; AMY25676; BCP07581; Tox21_110161; Tox21_201428; Tox21_300585; Tox21_500520; AC-472; BBL010484; CCG-38551; HB2775; LMPK12050218; s1342; STK801619; WHO 11073; AKOS001590147; Tox21_110161_1; CS-1534; CS-O-01020; DB01645; KS-5128; LP00520; LS-1266; SB17235; SDCCGSBI-0050503.P003; SMP1_000133; Genistein; 4',5,7-Trihydroxyisoflavone; NCGC00015479-01; NCGC00015479-02; NCGC00015479-04; NCGC00015479-05; NCGC00015479-06; NCGC00015479-07; NCGC00015479-08; NCGC00015479-10; NCGC00015479-11; NCGC00015479-12; NCGC00015479-13; NCGC00015479-14; NCGC00015479-15; NCGC00015479-16; NCGC00015479-17; NCGC00015479-18; NCGC00015479-19; NCGC00015479-20; NCGC00015479-38; NCGC00025005-01; NCGC00025005-02; NCGC00025005-03; NCGC00025005-04; NCGC00025005-05; NCGC00025005-06; NCGC00025005-07; NCGC00169711-01; NCGC00169711-02; NCGC00254275-01; NCGC00258979-01; NCGC00261205-01; HY-14596; NCI60_003369; SMR000112580; SY050124; EU-0100520; FT-0603395; FT-0668961; FT-0668962; G0272; GENISTEIN (CONSTITUENT OF RED CLOVER); SW203763-2; C06563; D11680; EN300-210743; G-2535; Genistein, synthetic, >=98% (HPLC), powder; K00046; US8552057, 2; AB00052696_09; AB00052696_12; A826657; GENISTEIN (CONSTITUENT OF SOY ISOFLAVONES); Q415957; GENISTEIN (CONSTITUENT OF RED CLOVER) [DSC]; Genistein, primary pharmaceutical reference standard; Q-100484; SR-01000075498-1; SR-01000075498-3; SR-01000075498-6; 3-(4-hydroxyphenyl)-5,7-bis(oxidanyl)chromen-4-one; 4 inverted exclamation marka,5,7-Trihydroxyisoflavone; BRD-K43797669-001-02-3; BRD-K43797669-001-03-1; BRD-K43797669-001-10-6; Genistein, from Glycine max (soybean), ~98% (HPLC); SR-01000075498-10; 5,7-dihydroxy-3-(4-hydroxyphenyl)-1-benzopyran-4-one; F0001-2388; GENISTEIN (CONSTITUENT OF SOY ISOFLAVONES) [DSC]; 4H-1-Benzopyran-4-one,7-dihydroxy-3-(4-hydroxyphenyl)-; 4h-1-benzopiran-4-ona, 5,7-dihidroxi-3-(4-hidroxifenil)-; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4 H-1-benzopyran-4-one; Genistein, United States Pharmacopeia (USP) Reference Standard; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-(ChemID); Genistein, Pharmaceutical Secondary Standard; Certified Reference Material Click to Show/Hide
Target(s)	Pro-epidermal growth factor (EGF)			Target Info
Structure
Structure	3D MOL		2D MOL
Formula	C15H10O5
Isosmiles	C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O
PubChem CID	5280961
InChI	InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H
InChIKey	TZBJGXHYKVUXJN-UHFFFAOYSA-N
IUPAC Name	5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
Pharmaceutical Properties	Molecule Weight	270.24	Polar area	87
	Complexity	411	xlogp Value	2.7
	Heavy Count	20	Rot Bonds	1
	Hbond acc	5	Hbond Donor	3

The activity data of This Payload

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Half Maximal Inhibitory Concentration (IC50)	0.1	ug/mL	A-431 cells	Skin squamous cell carcinoma	CVCL_0037	[1]
Half Maximal Inhibitory Concentration (IC50)	0.54	ug/mL	Neutrophil cells	Normal	Undisclosed	[2]
Half Maximal Inhibitory Concentration (IC50)	0.7	ug/mL	A-431 cells	Skin squamous cell carcinoma	CVCL_0037	[1]
Half Maximal Effective Concentration (EC50)	13.9	ug/mL	C8166 cells	Leukemia	CVCL_1099	[3]
Half Maximal Inhibitory Concentration (IC50)	4.18	ug/mL	B16-BL6 cells	Melanoma	CVCL_0157	[4]
Half Maximal Inhibitory Concentration (IC50)	6.99	ug/mL	Neutrophil cells	Normal	Undisclosed	[2]
Half Maximal Inhibitory Concentration (IC50)	1.3	nM	HEK-293T cells	Normal	CVCL_0063	[5]
Half Maximal Effective Concentration (EC50)	1.7	nM	SH-SY5Y cells	Bone marrow neuroblastoma	CVCL_0019	[6]
Half Maximal Inhibitory Concentration (IC50)	1000	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[7]
Half Maximal Inhibitory Concentration (IC50)	>1000	nM	RAW264.7 cells	Monocytic-macrophage leukemia	CVCL_0493	[8]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	10000	nM	CCRF-CEM cells	T acute lymphoblastic leukemia	CVCL_0207	[9]
Half Maximal Inhibitory Concentration (IC50)	10000	nM	LNCaP cells	Prostate carcinoma	CVCL_0395	[10]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	10000	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[11]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	PC-3 cells	Prostate carcinoma	CVCL_0035	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[9]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	U-937 cells	Adult acute monocytic leukemia	CVCL_0007	[12]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	U-251MG cells	Astrocytoma	CVCL_0021	[9]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	Caco-2 cells	Colon adenocarcinoma	CVCL_0025	[13]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	Hep-G2 cells	Hepatoblastoma	CVCL_0027	[14]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	DU145 cells	Prostate carcinoma	CVCL_0105	[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	COLO 205 cells	Colon adenocarcinoma	CVCL_0218	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	HT-29 cells	Colon adenocarcinoma	CVCL_0320	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	MDA-MB-435 cells	Amelanotic melanoma	CVCL_0417	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SK-MEL-28 cells (BRAF inhibitor resistant)	Cutaneous melanoma	CVCL_0526	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SK-MEL-5 cells	Cutaneous melanoma	CVCL_0527	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	T-47D cells	Invasive breast carcinoma	CVCL_0553	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	NCI-ADR-RES cells	High grade ovarian serous adenocarcinoma	CVCL_1452	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	NCI-H23 cells	Lung adenocarcinoma	CVCL_1547	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	OVCAR-5 cells	Ovarian serous adenocarcinoma	CVCL_1628	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	OVCAR-8 cells	High grade ovarian serous adenocarcinoma	CVCL_1629	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SF539 cells	Gliosarcoma	CVCL_1691	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SF268 cells	Astrocytoma	CVCL_1689	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[9]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	HEK293 cells	Normal	CVCL_0045	[16]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	Sf9 cells	Normal	CVCL_0549	[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	HCC 2998 cells	Colon adenocarcinoma	CVCL_1266	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	HOP-92 cells	Non-small cell lung carcinoma	CVCL_1286	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	KM12 cells	Colon adenocarcinoma	CVCL_1331	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	M14 cells	Melanoma	CVCL_1395	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	Malme-3M cells	Melanoma	CVCL_1438	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	OVCAR-4 cells	Ovarian adenocarcinoma	CVCL_1627	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	TK-10 cells	Renal carcinoma	CVCL_1773	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	UACC-62 cells	Melanoma	CVCL_1780	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	MDA-N cells	Breast carcinoma	CVCL_1910	[9]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	L02 cells	Cervical carcinoma	CVCL_6926	[14]
Half Maximal Inhibitory Concentration (IC50)	10469	nM	Farage cells	Normal	CVCL_0214	[18]
Half Maximal Effective Concentration (EC50)	108000	nM	A-431 cells	Skin squamous cell carcinoma	CVCL_0037	[19]
Half Maximal Inhibitory Concentration (IC50)	10924	nM	U-937 cells	Adult acute monocytic leukemia	CVCL_0007	[18]
Half Maximal Inhibitory Concentration (IC50)	11000	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[20]
Half Maximal Inhibitory Concentration (IC50)	11000	nM	Ventricular myocyte cells	Normal	Undisclosed	[21]
Half Maximal Inhibitory Concentration (IC50)	11000	nM	Ventricular myocyte cells	Normal	Undisclosed	[22]
Half Maximal Inhibitory Concentration (IC50)	11013	nM	Platelet cells	Normal	Undisclosed	[18]
Half Maximal Inhibitory Concentration (IC50)	1110	nM	Neutrophil cells	Normal	Undisclosed	[23]
Half Maximal Inhibitory Concentration (IC50)	11400	nM	RAW264.7 cells	Monocytic-macrophage leukemia	CVCL_0493	[24]
Half Maximal Inhibitory Concentration (IC50)	1300000	nM	MDA-kb2 cells	Breast adenocarcinoma	CVCL_6421	[25]
Half Maximal Inhibitory Concentration (IC50)	135	nM	Sf9 cells	Normal	CVCL_0549	[18]
Half Maximal Effective Concentration (EC50)	14200	nM	FRT cells	Normal	CVCL_A6IE	[26]
Half Maximal Effective Concentration (EC50)	14400	nM	Huh-7 cells	Adult hepatocellular carcinoma	CVCL_0336	[27]
Half Maximal Inhibitory Concentration (IC50)	14910	nM	Farage cells	Normal	CVCL_0214	[18]
Half Maximal Inhibitory Concentration (IC50)	15100	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[28]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	15848.93	nM	SNB-75 cells	Glioblastoma	CVCL_1706	[29]
Half Maximal Inhibitory Concentration (IC50)	16500	nM	HEK293 cells	Normal	CVCL_0045	[30]
Half Maximal Inhibitory Concentration (IC50)	16918	nM	Farage cells	Normal	CVCL_0214	[18]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	16982.44	nM	NCI-ADR-RES cells	High grade ovarian serous adenocarcinoma	CVCL_1452	[31]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	17000	nM	MDA-MB-436 cells	Metastasis of ductal carcinoma	CVCL_0623	[11]
Half Maximal Inhibitory Concentration (IC50)	17442	nM	HEK293 cells	Normal	CVCL_0045	[18]
Half Maximal Inhibitory Concentration (IC50)	17560	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[32]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	17782.79	nM	NCI-H522 cells	Non-small cell lung carcinoma	CVCL_1567	[29]
Half Maximal Inhibitory Concentration (IC50)	18100	nM	RAW cells	Monocytic-macrophage leukemia	Undisclosed	[33]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	18197.01	nM	LOX IMVI cells	Melanoma	CVCL_1381	[29]
Half Maximal Inhibitory Concentration (IC50)	183900	nM	BALB/3T3 cells	Normal	CVCL_0184	[34]
Half Maximal Effective Concentration (EC50)	19.95	nM	HEK293 cells	Normal	CVCL_0045	[35]
Half Maximal Inhibitory Concentration (IC50)	19100	nM	RAW264.7 cells	Monocytic-macrophage leukemia	CVCL_0493	[36]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	19498.45	nM	ACHN cells	Renal adenocarcinoma	CVCL_1067	[29]
Half Maximal Inhibitory Concentration (IC50)	19904	nM	CHO cells	Normal	CVCL_0213	[18]
Half Maximal Inhibitory Concentration (IC50)	>19952.62	nM	Vero C1008 cells	Normal	CVCL_0574	[37]
Half Maximal Inhibitory Concentration (IC50)	2.88	nM	Sf9 cells	Normal	CVCL_0549	[18]
Half Maximal Inhibitory Concentration (IC50)	20000	nM	Huh-7 cells	Adult hepatocellular carcinoma	CVCL_0336	[38]
Half Maximal Inhibitory Concentration (IC50)	20000	nM	Ventricular myocyte cells	Normal	Undisclosed	[21]
Half Maximal Inhibitory Concentration (IC50)	>20000	nM	Vero C1008 cells	Normal	CVCL_0574	[37]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	21877.62	nM	DMS-273 cells	Small cell lung carcinoma	CVCL_1176	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	21877.62	nM	MCF-12A cells	Normal	CVCL_3744	[31]
Half Maximal Inhibitory Concentration (IC50)	22000	nM	HEK293 cells	Normal	CVCL_0045	[39]
Half Maximal Inhibitory Concentration (IC50)	2210	nM	HEK293 cells	Normal	CVCL_0045	[30]
Half Maximal Effective Concentration (EC50)	240	nM	Ishikawa cells	Endometrial adenocarcinoma	CVCL_2529	[40]
Half Maximal Inhibitory Concentration (IC50)	24000	nM	LNCaP cells	Prostate carcinoma	CVCL_0395	[10]
Half Maximal Inhibitory Concentration (IC50)	24000	nM	NIH3T3 cells	Normal	CVCL_0594	[28]
Half Maximal Inhibitory Concentration (IC50)	24800	nM	Hep-G2 cells	Hepatoblastoma	CVCL_0027	[41]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	24945.95	nM	UO-31 cells	Renal carcinoma	CVCL_1911	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	25118.86	nM	HCT 116 cells	Colon carcinoma	CVCL_0291	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	25118.86	nM	MKN-1 cells	Gastric carcinoma	CVCL_1415	[29]
Half Maximal Inhibitory Concentration (IC50)	25120	nM	HEK293 cells	Normal	CVCL_0045	[16]
Half Maximal Inhibitory Concentration (IC50)	2520	nM	BTI-TN-5B1-4 cells	Normal	CVCL_C190	[18]
Half Maximal Inhibitory Concentration (IC50)	26000	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[42]
Half Maximal Inhibitory Concentration (IC50)	26000	nM	RAW264.7 cells	Monocytic-macrophage leukemia	CVCL_0493	[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	26302.68	nM	A-549 cells	Lung adenocarcinoma	CVCL_0023	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	26302.68	nM	NCI-H460 cells	Lung large cell carcinoma	CVCL_0459	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	26302.68	nM	SF539 cells	Gliosarcoma	CVCL_1691	[29]
Half Maximal Inhibitory Concentration (IC50)	26500	nM	RAW264.7 cells	Monocytic-macrophage leukemia	CVCL_0493	[44]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	26915.35	nM	NCI-ADR-RES cells	High grade ovarian serous adenocarcinoma	CVCL_1452	[31]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	26915.35	nM	HBC-5 cells	Breast carcinoma	CVCL_B497	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	27542.29	nM	NCI-H226 cells	Pleural epithelioid mesothelioma	CVCL_1544	[29]
Half Maximal Inhibitory Concentration (IC50)	27700	nM	WiDr cells	Colon adenocarcinoma	CVCL_2760	[28]
Half Maximal Effective Concentration (EC50)	278000	nM	A-431 cells	Skin squamous cell carcinoma	CVCL_0037	[19]
Half Maximal Inhibitory Concentration (IC50)	28400	nM	BV-2 cells	Normal	CVCL_0182	[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	28840.32	nM	SF-295 cells	Glioblastoma	CVCL_1690	[29]
Half Maximal Inhibitory Concentration (IC50)	29.4	nM	HEK-293T cells	Normal	CVCL_0063	[5]
Half Maximal Inhibitory Concentration (IC50)	29200	nM	NHEM693 cells	Normal	CVCL_B448	[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	29716.66	nM	ACHN cells	Renal adenocarcinoma	CVCL_1067	[9]
Half Maximal Inhibitory Concentration (IC50)	30000	nM	BxPC-3 CDX model cells	Pancreatic ductal adenocarcinoma	CVCL_0186	[47]
Half Maximal Inhibitory Concentration (IC50)	>30000	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[42]
Half Maximal Inhibitory Concentration (IC50)	30000	nM	Sf9 cells	Normal	CVCL_0549	[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	30199.52	nM	HCT 15 cells	Colon adenocarcinoma	CVCL_0292	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	30199.52	nM	MKN7 cells	Gastric tubular adenocarcinoma	CVCL_1417	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	30199.52	nM	SF268 cells	Astrocytoma	CVCL_1689	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	30199.52	nM	MCF-12A cells	Normal	CVCL_3744	[31]
Half Maximal Inhibitory Concentration (IC50)	30650	nM	LNCaP cells	Prostate carcinoma	CVCL_0395	[13]
Half Maximal Inhibitory Concentration (IC50)	31000	nM	HEK293 cells	Normal	CVCL_0045	[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	31622.78	nM	OVCAR-3 cells (FZD7 overexpression)	Ovarian serous adenocarcinoma	CVCL_0465	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	32359.37	nM	MKN45 cells	Gastric adenocarcinoma	CVCL_0434	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	32359.37	nM	NCI-ADR-RES cells	High grade ovarian serous adenocarcinoma	CVCL_1452	[31]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	32359.37	nM	MCF-12A cells	Normal	CVCL_3744	[31]
Half Maximal Inhibitory Concentration (IC50)	32900	nM	Vero cells	Normal	CVCL_0059	[48]
Half Maximal Inhibitory Concentration (IC50)	34900	nM	HCT 116 cells	Colon carcinoma	CVCL_0291	[13]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	35481.34	nM	OVCAR-8 cells	High grade ovarian serous adenocarcinoma	CVCL_1629	[29]
Half Maximal Effective Concentration (EC50)	35695.8	nM	UoC-B1 cells	B acute lymphoblastic leukemia	CVCL_A296	[49]
Half Maximal Inhibitory Concentration (IC50)	36000	nM	SK-MEL-2 cells (MEK inhibitor-resistant)	Melanoma	CVCL_0069	[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	36307.81	nM	NCI-H23 cells	Lung adenocarcinoma	CVCL_1547	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	36307.81	nM	MKN-74 cells	Stomach adenocarcinoma	CVCL_2791	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	36391.5	nM	NCI-H522 cells	Non-small cell lung carcinoma	CVCL_1567	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	37153.52	nM	MDA-MB-231 cells (5T4 overexpression)	Breast adenocarcinoma	CVCL_0062	[29]
Half Maximal Inhibitory Concentration (IC50)	37400	nM	LNCaP cells	Prostate carcinoma	CVCL_0395	[15]
Half Maximal Inhibitory Concentration (IC50)	3890.45	nM	CHO cells	Normal	CVCL_0213	[51]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	38904.51	nM	LNCaP cells	Prostate carcinoma	CVCL_0395	[31]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	38904.51	nM	SNB-78 cells	Glioblastoma	CVCL_B321	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	39810.72	nM	MKN-28 cells	Gastric epithelial carcinoma	CVCL_1416	[29]
Half Maximal Effective Concentration (EC50)	4.1	nM	HeLa cells	Endocervical adenocarcinoma	CVCL_0030	[6]
Half Maximal Effective Concentration (EC50)	403000	nM	SK-BR-3 cells	Breast adenocarcinoma	CVCL_0033	[19]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	40364.54	nM	MOLT-4 cells	Adult T acute lymphoblastic leukemia	CVCL_0013	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	40738.03	nM	RXF 631 cells	Renal carcinoma	CVCL_A780	[29]
Half Maximal Inhibitory Concentration (IC50)	41670	nM	AGS cells	Gastric adenocarcinoma	CVCL_0139	[13]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	41975.9	nM	NCI-H460 cells	Lung large cell carcinoma	CVCL_0459	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	42657.95	nM	PC-3 cells	Prostate carcinoma	CVCL_0035	[31]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	42657.95	nM	U-251MG cells	Astrocytoma	CVCL_0021	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	42657.95	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[29]
Half Maximal Inhibitory Concentration (IC50)	43000	nM	MDA-MB-231 cells (5T4 overexpression)	Breast adenocarcinoma	CVCL_0062	[50]
Half Maximal Inhibitory Concentration (IC50)	43090	nM	A-549 cells	Lung adenocarcinoma	CVCL_0023	[13]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	43151.91	nM	786-O cells	Renal cell carcinoma	CVCL_1051	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	43651.58	nM	OVCAR-4 cells	Ovarian adenocarcinoma	CVCL_1627	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	43651.58	nM	BSY-1 cells	Breast carcinoma	CVCL_B499	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	43651.58	nM	HBC-4 cells	Breast carcinoma	CVCL_B496	[29]
Half Maximal Effective Concentration (EC50)	4400	nM	NIH3T3 cells	Normal	CVCL_0594	[52]
Half Maximal Inhibitory Concentration (IC50)	44000	nM	LN-229 cells	Glioblastoma	CVCL_0393	[50]
Half Maximal Inhibitory Concentration (IC50)	45200	nM	Hepa-1c1c7 cells	Hepatocellular carcinoma of the mouse	CVCL_0328	[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	45708.82	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[31]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	45708.82	nM	HCC 2998 cells	Colon adenocarcinoma	CVCL_1266	[29]
Half Maximal Inhibitory Concentration (IC50)	46000	nM	BT-20 cells	Invasive breast carcinoma of no special type	CVCL_0178	[47]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	46773.51	nM	St-4 cells	Stomach carcinoma	CVCL_H265	[29]
Half Maximal Inhibitory Concentration (IC50)	47000	nM	NCI-H460 cells	Lung large cell carcinoma	CVCL_0459	[50]
Half Maximal Inhibitory Concentration (IC50)	47290	nM	DU145 cells	Prostate carcinoma	CVCL_0105	[13]
Half Maximal Effective Concentration (EC50)	48	nM	HeLa cells	Endocervical adenocarcinoma	CVCL_0030	[6]
Half Maximal Inhibitory Concentration (IC50)	48000	nM	U-937 cells	Adult acute monocytic leukemia	CVCL_0007	[12]
Half Maximal Inhibitory Concentration (IC50)	48000	nM	T-47D cells	Invasive breast carcinoma	CVCL_0553	[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	48977.88	nM	DMS 114 cells	Lung small cell carcinoma	CVCL_1174	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	49203.95	nM	SW620 cells	Colon adenocarcinoma	CVCL_0547	[9]
Half Maximal Inhibitory Concentration (IC50)	50000	nM	PC-3 cells	Prostate carcinoma	CVCL_0035	[47]
Half Maximal Inhibitory Concentration (IC50)	50000	nM	HT-29 cells	Colon adenocarcinoma	CVCL_0320	[50]
Half Maximal Inhibitory Concentration (IC50)	50000	nM	COLO357 cells	Pancreatic carcinoma	CVCL_0221	[47]
Half Maximal Inhibitory Concentration (IC50)	>50000	nM	RAW264.7 cells	Monocytic-macrophage leukemia	CVCL_0493	[54]
Half Maximal Inhibitory Concentration (IC50)	>500000	nM	Melan-a cells	Normal	CVCL_4624	[55]
Half Maximal Effective Concentration (EC50)	501.19	nM	HEK293 cells	Normal	CVCL_0045	[35]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	50118.72	nM	DU145 cells	Prostate carcinoma	CVCL_0105	[31]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	50118.72	nM	OVCAR-5 cells	Ovarian serous adenocarcinoma	CVCL_1628	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	50118.72	nM	KM12 cells	Colon adenocarcinoma	CVCL_1331	[29]
Half Maximal Inhibitory Concentration (IC50)	510	nM	Ishikawa cells	Endometrial adenocarcinoma	CVCL_2529	[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	52480.75	nM	SN12C cells	Renal cell carcinoma	CVCL_1705	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	52480.75	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[31]
Half Maximal Inhibitory Concentration (IC50)	52780	nM	HT-29 cells	Colon adenocarcinoma	CVCL_0320	[13]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	53703.18	nM	HT-29 cells	Colon adenocarcinoma	CVCL_0320	[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	54954.09	nM	SF-295 cells	Glioblastoma	CVCL_1690	[9]
Half Maximal Inhibitory Concentration (IC50)	55000	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022	[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	56754.46	nM	SR cells	Leukemia	CVCL_1711	[9]
Half Maximal Inhibitory Concentration (IC50)	57500	nM	Cardiac Muscle cells	Normal	Undisclosed	[22]
Half Maximal Inhibitory Concentration (IC50)	57830	nM	Melan-a cells	Normal	CVCL_4624	[55]
Half Maximal Inhibitory Concentration (IC50)	58180	nM	HEK293 cells	Normal	CVCL_0045	[16]
Half Maximal Effective Concentration (EC50)	59338	nM	SEM cells	Leukemia	CVCL_0095	[49]
Half Maximal Inhibitory Concentration (IC50)	61.33	nM	SF-126 cells	Glioblastoma	CVCL_1688
Half Maximal Cell Growth Inhibitory Concentration (GI50)	61659.5	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[31]
Half Maximal Effective Concentration (EC50)	6170	nM	FRT cells	Normal	CVCL_A6IE	[26]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	62373.48	nM	A-549 cells	Lung adenocarcinoma	CVCL_0023	[9]
Half Maximal Inhibitory Concentration (IC50)	62710	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[13]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	63095.73	nM	EKVX cells	Non-small cell lung carcinoma	CVCL_1195	[9]
Half Maximal Inhibitory Concentration (IC50)	64000	nM	A-549 cells	Lung adenocarcinoma	CVCL_0023	[50]
Half Maximal Inhibitory Concentration (IC50)	65000	nM	LNCaP cells	Prostate carcinoma	CVCL_0395	[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	65162.84	nM	Hs 578T cells	Invasive breast carcinoma	CVCL_0332	[9]
Half Maximal Inhibitory Concentration (IC50)	65170	nM	PC-3 cells	Prostate carcinoma	CVCL_0035	[13]
Half Maximal Inhibitory Concentration (IC50)	6720	nM	Neutrophil cells	Normal	Undisclosed	[58]
Half Maximal Effective Concentration (EC50)	67694.5	nM	Hep-G2 cells	Hepatoblastoma	CVCL_0027	[49]
Half Maximal Inhibitory Concentration (IC50)	67990	nM	HEK293 cells	Normal	CVCL_0045	[16]
Half Maximal Inhibitory Concentration (IC50)	68600	nM	PC-3 cells	Prostate carcinoma	CVCL_0035	[15]
Half Maximal Inhibitory Concentration (IC50)	690	nM	Neutrophil cells	Normal	Undisclosed	[58]
Half Maximal Inhibitory Concentration (IC50)	6900	nM	MDCK cells	Normal	CVCL_0422	[59]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	69823.24	nM	HL-60 cells	Adult acute myeloid leukemia	CVCL_0002	[9]
Half Maximal Effective Concentration (EC50)	7000	nM	FRT cells	Normal	CVCL_A6IE	[60]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	71614.34	nM	IGROV-1 cells	Ovarian endometrioid adenocarcinoma	CVCL_1304	[9]
Half Maximal Inhibitory Concentration (IC50)	72000	nM	U-937 cells	Adult acute monocytic leukemia	CVCL_0007	[12]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	72945.75	nM	HCT 15 cells	Colon adenocarcinoma	CVCL_0292	[9]
Half Maximal Effective Concentration (EC50)	73	nM	HeLa cells	Endocervical adenocarcinoma	CVCL_0030	[61]
Half Maximal Inhibitory Concentration (IC50)	73000	nM	COLO 201 cells	Colon adenocarcinoma	CVCL_1987	[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	74131.02	nM	NCI-H226 cells	Pleural epithelioid mesothelioma	CVCL_1544	[9]
Half Maximal Inhibitory Concentration (IC50)	77000	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[20]
Half Maximal Inhibitory Concentration (IC50)	7720	nM	Platelet cells	Normal	Undisclosed	[18]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	77803.66	nM	RPMI-8226 cells	Plasma cell myeloma	CVCL_0014	[9]
Half Maximal Inhibitory Concentration (IC50)	79000	nM	BxPC-3 CDX model cells	Pancreatic ductal adenocarcinoma	CVCL_0186	[50]
Half Maximal Inhibitory Concentration (IC50)	79210	nM	B16-F10 cells	Mouse melanoma	CVCL_0159	[4]
Half Maximal Inhibitory Concentration (IC50)	8000	nM	ANN-1 cells	Normal	CVCL_9242	[28]
Half Maximal Effective Concentration (EC50)	8200	nM	CHO cells	Normal	CVCL_0213	[26]
Half Maximal Effective Concentration (EC50)	8480	nM	CHO cells	Normal	CVCL_0213	[26]
Half Maximal Effective Concentration (EC50)	>86206.9	nM	SUP-B15 cells	B-lymphoblastic leukemia	CVCL_0103	[49]
Half Maximal Effective Concentration (EC50)	>86206.9	nM	KOPN-8 cells	Leukemia	CVCL_1866	[49]
Half Maximal Effective Concentration (EC50)	>86206.9	nM	BJ cells	Normal	CVCL_3653	[49]
Half Maximal Inhibitory Concentration (IC50)	87000	nM	PANC-1 cells	Pancreatic ductal adenocarcinoma	CVCL_0480	[50]
Half Maximal Inhibitory Concentration (IC50)	8800	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[59]
Half Maximal Inhibitory Concentration (IC50)	88000	nM	Human umbilical vein endothelial cells(HUVEC)	Normal	Undisclosed	[62]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	88307.99	nM	BT-549 cells	Breast ductal carcinoma	CVCL_1092	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	89125.09	nM	SK-OV-3 cells (FZD7 overexpression)	Ovarian serous cystadenocarcinoma	CVCL_0532	[29]
Half Maximal Inhibitory Concentration (IC50)	89410	nM	T98G cells	Glioblastoma	CVCL_0556	[13]
Half Maximal Inhibitory Concentration (IC50)	9100	nM	Balb/MK cells	Normal	CVCL_1B29	[63]
Half Maximal Inhibitory Concentration (IC50)	9120.11	nM	CHO cells	Normal	CVCL_0213	[51]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	92044.96	nM	SNB-19 cells	Astrocytoma	CVCL_0535	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	92469.82	nM	DU145 cells	Prostate carcinoma	CVCL_0105	[9]
Half Maximal Effective Concentration (EC50)	956	nM	HeLa cells	Endocervical adenocarcinoma	CVCL_0030	[61]
Half Maximal Inhibitory Concentration (IC50)	96700	nM	SK-BR-3 cells	Breast adenocarcinoma	CVCL_0033	[13]
Half Maximal Effective Concentration (EC50)	97000	nM	SK-BR-3 cells	Breast adenocarcinoma	CVCL_0033	[19]

Each Antibody-drug Conjugate Related to This Payload

References

Ref 1	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60. doi: 10.1021/np50089a001.
Ref 2	A novel alkaloid, aristopyridinone A and anti-inflammatory phenanthrenes isolated from Aristolochia manshuriensis. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1792-4. doi: 10.1016/j.bmcl.2011.01.067. Epub 2011 Jan 22.
Ref 3	Design and discovery of flavonoid-based HIV-1 integrase inhibitors targeting both the active site and the interaction with LEDGF/p75. Bioorg Med Chem. 2014 Jun 15;22(12):3146-58. doi: 10.1016/j.bmc.2014.04.016. Epub 2014 Apr 19.
Ref 4	Insights into tyrosinase inhibition by compounds isolated from Greyia radlkoferi Szyszyl using biological activity, molecular docking and gene expression analysis. Bioorg Med Chem. 2016 Nov 15;24(22):5953-5959. doi: 10.1016/j.bmc.2016.09.054. Epub 2016 Sep 22.
Ref 5	Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. doi: 10.1016/j.bmcl.2005.08.010. Epub 2005 Oct 10.
Ref 6	Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes. J Med Chem. 2002 Mar 28;45(7):1399-401. doi: 10.1021/jm015577l.
Ref 7	Dihydro-resveratrol--a potent dietary polyphenol. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6149-51. doi: 10.1016/j.bmcl.2010.08.002. Epub 2010 Aug 5.
Ref 8	Chemical Constituents of Apios americana Tubers and Their Inhibitory Activities on Nitric Oxide Production in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages. J Nat Prod. 2018 Jul 27;81(7):1598-1603. doi: 10.1021/acs.jnatprod.8b00182. Epub 2018 Jun 22.
Ref 9	PubChem BioAssay data set.
Ref 10	Design, synthesis, and evaluation of the antiproliferative activity of hydantoin-derived antiandrogen-genistein conjugates. Bioorg Med Chem. 2018 May 1;26(8):1481-1487. doi: 10.1016/j.bmc.2018.01.009. Epub 2018 Feb 16.
Ref 11	Isoflavones with unusually modified B-rings and their evaluation as antiproliferative agents. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6473-6. doi: 10.1016/j.bmcl.2009.08.084. Epub 2009 Aug 28.
Ref 12	Rotenoids and flavonoids with anti-invasion of HT1080, anti-proliferation of U937, and differentiation-inducing activity in HL-60 from Erycibe expansa. Bioorg Med Chem. 2007 Feb 1;15(3):1539-46. doi: 10.1016/j.bmc.2006.09.024. Epub 2006 Dec 8.
Ref 13	Synthetic conjugates of genistein affecting proliferation and mitosis of cancer cells. Bioorg Med Chem. 2011 Jan 1;19(1):295-305. doi: 10.1016/j.bmc.2010.11.024. Epub 2010 Nov 11.
Ref 14	Phosphoramidate protides of five flavones and their antiproliferative activity against HepG2 and L-O2 cell lines. Eur J Med Chem. 2016 Apr 13;112:196-208. doi: 10.1016/j.ejmech.2016.02.012. Epub 2016 Feb 18.
Ref 15	A new class of hybrid anticancer agents inspired by the synergistic effects of curcumin and genistein: Design, synthesis, and anti-proliferative evaluation. Bioorg Med Chem Lett. 2015 Oct 15;25(20):4553-6. doi: 10.1016/j.bmcl.2015.08.064. Epub 2015 Aug 24.
Ref 16	Discovery of (E)-5-(benzylideneamino)-1H-benzo[d]imidazol-2(3H)-one derivatives as inhibitors for PTK6. Bioorg Med Chem Lett. 2014 Oct 1;24(19):4659-4663. doi: 10.1016/j.bmcl.2014.08.036. Epub 2014 Aug 23.
Ref 17	Targeting DNA methylation with small molecules: what's next?. J Med Chem. 2015 Mar 26;58(6):2569-83. doi: 10.1021/jm500843d. Epub 2014 Dec 4.
Ref 18	DrugMatrix in vitro pharmacology data.
Ref 19	Epigallocatechin 3-O-gallate induces 67 kDa laminin receptor-mediated cell death accompanied by downregulation of ErbB proteins and altered lipid raft clustering in mammary and epidermoid carcinoma cells. J Nat Prod. 2014 Feb 28;77(2):250-7. doi: 10.1021/np4007712. Epub 2014 Jan 23.
Ref 20	Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer. J Med Chem. 1996 Aug 30;39(18):3461-9. doi: 10.1021/jm950938g.
Ref 21	Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment. J Appl Toxicol. 2012 Oct;32(10):858-66. doi: 10.1002/jat.2784. Epub 2012 Jul 3.
Ref 22	IC50 data for the L-type calcium channel extracted from a set of literature articles.
Ref 23	Anti-inflammatory principles from Lindera aggregata. Bioorg Med Chem Lett. 2020 Jul 1;30(13):127224. doi: 10.1016/j.bmcl.2020.127224. Epub 2020 Apr 27.
Ref 24	Anti-inflammatory and Antiosteoporosis Flavonoids from the Rhizomes of Helminthostachys zeylanica. J Nat Prod. 2017 Feb 24;80(2):246-253. doi: 10.1021/acs.jnatprod.5b01164. Epub 2017 Feb 7.
Ref 25	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10. doi: 10.1016/j.bmcl.2009.06.073. Epub 2009 Jun 23.
Ref 26	Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. J Med Chem. 2021 Jun 10;64(11):7241-7260. doi: 10.1021/acs.jmedchem.1c00343. Epub 2021 May 24.
Ref 27	Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy. Eur J Med Chem. 2012 Jun;52:33-43. doi: 10.1016/j.ejmech.2012.03.002. Epub 2012 Mar 8.
Ref 28	Structural studies on bioactive compounds. 23. Synthesis of polyhydroxylated 2-phenylbenzothiazoles and a comparison of their cytotoxicities and pharmacological properties with genistein and quercetin. J Med Chem. 1994 May 27;37(11):1689-95. doi: 10.1021/jm00037a020.
Ref 29	(S)-Erypoegin K, an isoflavone isolated from Erythrina poeppigiana, is a novel inhibitor of topoisomerase II: Induction of G2 phase arrest in human gastric cancer cells. Bioorg Med Chem. 2021 Jan 15;30:115904. doi: 10.1016/j.bmc.2020.115904. Epub 2020 Dec 5.
Ref 30	Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99. doi: 10.1021/jm800054h. Epub 2008 Jun 6.
Ref 31	Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I. J Med Chem. 2011 May 26;54(10):3506-23. doi: 10.1021/jm101619e. Epub 2011 Apr 22.
Ref 32	Cells lacking DNA topoisomerase II beta are resistant to genistein. J Nat Prod. 2007 May;70(5):763-7. doi: 10.1021/np060609z. Epub 2007 Apr 6.
Ref 33	Synthetic 2',5'-dimethoxychalcones as G(2)/M arrest-mediated apoptosis-inducing agents and inhibitors of nitric oxide production in rat macrophages. Eur J Med Chem. 2007 May;42(5):660-8. doi: 10.1016/j.ejmech.2006.12.009. Epub 2007 Jan 9.
Ref 34	Activities of plant-derived phenols in a fibroblast cell culture model. J Nat Prod. 1999 Mar;62(3):481-3. doi: 10.1021/np9801559.
Ref 35	The A-CD analogue of 16 beta,17 alpha-estriol is a potent and highly selective estrogen receptor beta agonist. Medchemcomm. 2013;4(11):1439-1442.
Ref 36	Chisopanins A-K, 11 new protolimonoids from Chisocheton paniculatus and their anti-inflammatory activities. Bioorg Med Chem. 2011 Feb 15;19(4):1409-17. doi: 10.1016/j.bmc.2011.01.007. Epub 2011 Jan 11.
Ref 37	Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity.
Ref 38	Flavones as isosteres of 4(1H)-quinolones: discovery of ligand efficient and dual stage antimalarial lead compounds. Eur J Med Chem. 2013 Nov;69:872-80. doi: 10.1016/j.ejmech.2013.09.008. Epub 2013 Sep 20.
Ref 39	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. doi: 10.1016/j.bmc.2008.02.078. Epub 2008 Feb 29.
Ref 40	Estrogen Receptor (ER) Subtype Selectivity Identifies 8-Prenylapigenin as an ER Agonist from Glycyrrhiza inflata and Highlights the Importance of Chemical and Biological Authentication. J Nat Prod. 2018 Apr 27;81(4):966-975. doi: 10.1021/acs.jnatprod.7b01070. Epub 2018 Apr 11.
Ref 41	Cornusides A-O, Bioactive Iridoid Glucoside Dimers from the Fruit of Cornus officinalis. J Nat Prod. 2017 Dec 22;80(12):3103-3111. doi: 10.1021/acs.jnatprod.6b01127. Epub 2017 Nov 15.
Ref 42	New bioactive flavonoids and stilbenes in cub resin insecticide. J Nat Prod. 1999 Feb;62(2):205-10. doi: 10.1021/np980119+.
Ref 43	Synthesis of a novel series of diphenolic chromone derivatives as inhibitors of NO production in LPS-activated RAW264.7 macrophages. Bioorg Med Chem. 2010 Apr 15;18(8):2864-71. doi: 10.1016/j.bmc.2010.03.020. Epub 2010 Mar 12.
Ref 44	Synthesis, anti-inflammatory, and antioxidant activities of 18beta-glycyrrhetinic acid derivatives as chemical mediators and xanthine oxidase inhibitors. Bioorg Med Chem. 2009 Apr 1;17(7):2785-92. doi: 10.1016/j.bmc.2009.02.025. Epub 2009 Feb 21.
Ref 45	Anti-inflammatory isoflavones and isoflavanones from the roots of Pongamia pinnata (L.) Pierre. Bioorg Med Chem Lett. 2018 Apr 1;28(6):1050-1055. doi: 10.1016/j.bmcl.2018.02.026. Epub 2018 Feb 15.
Ref 46	Melanin synthesis inhibitors from Lespedeza floribunda. J Nat Prod. 2009 Feb 27;72(2):194-203. doi: 10.1021/np800395j.
Ref 47	Synthesis, molecular characterization, and biological activity of novel synthetic derivatives of chromen-4-one in human cancer cells. J Med Chem. 2006 Jun 29;49(13):3800-8. doi: 10.1021/jm051068y.
Ref 48	Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities. J Nat Prod. 2006 Jan;69(1):43-9. doi: 10.1021/np0502600.
Ref 49	Novel vitexin-inspired scaffold against leukemia. Eur J Med Chem. 2018 Feb 25;146:501-510. doi: 10.1016/j.ejmech.2018.01.004. Epub 2018 Jan 31.
Ref 50	Polyphenolic Phytochemicals in Cancer Prevention and Therapy: Bioavailability versus Bioefficacy. J Med Chem. 2017 Dec 14;60(23):9413-9436. doi: 10.1021/acs.jmedchem.6b01026. Epub 2017 Jul 11.
Ref 51	Structure-based identification of OATP1B1/3 inhibitors. Mol Pharmacol. 2013 Jun;83(6):1257-67. doi: 10.1124/mol.112.084152. Epub 2013 Apr 9.
Ref 52	Activation of CFTR by UCCF-029 and genistein. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3874-7. doi: 10.1016/j.bmcl.2008.06.051. Epub 2008 Jun 19.
Ref 53	Potential cncer chemopreventive flavonoids from the stems of Tephrosia toxicaria. J Nat Prod. 2003 Sep;66(9):1166-70. doi: 10.1021/np0302100.
Ref 54	Inhibitory constituents of Sophora tonkinensis on nitric oxide production in RAW 264.7 macrophages. Bioorg Med Chem Lett. 2015 Feb 15;25(4):960-2. doi: 10.1016/j.bmcl.2014.12.012. Epub 2014 Dec 13.
Ref 55	Natural ortho-dihydroxyisoflavone derivatives from aged Korean fermented soybean paste as potent tyrosinase and melanin formation inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1162-4. doi: 10.1016/j.bmcl.2009.12.021. Epub 2009 Dec 6.
Ref 56	Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis. J Nat Prod. 2002 Dec;65(12):1749-53. doi: 10.1021/np0201164.
Ref 57	Another look at phenolic compounds in cancer therapy the effect of polyphenols on ubiquitin-proteasome system. Eur J Med Chem. 2019 Apr 1;167:291-311. doi: 10.1016/j.ejmech.2019.01.044. Epub 2019 Jan 30.
Ref 58	Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, induces the production of anti-inflammatory cyclodepsipeptides from Beauveria felina. J Nat Prod. 2013 Jul 26;76(7):1260-6. doi: 10.1021/np400143j. Epub 2013 Jul 3.
Ref 59	Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem. 2011 Mar 15;19(6):2090-102. doi: 10.1016/j.bmc.2010.12.043. Epub 2010 Dec 30.
Ref 60	Fluorinated F508-CFTR correctors and potentiators for PET imaging. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1602-5. doi: 10.1016/j.bmcl.2011.12.128. Epub 2012 Jan 3.
Ref 61	Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. J Med Chem. 2006 Apr 20;49(8):2440-55. doi: 10.1021/jm0509389.
Ref 62	In-silico fragment-based identification of novel angiogenesis inhibitors. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4551-6. doi: 10.1016/j.bmcl.2007.05.104. Epub 2007 Jun 15.
Ref 63	[(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase. J Med Chem. 1995 Jun 23;38(13):2441-8. doi: 10.1021/jm00013a020.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.

Payload Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)